Featured Research

from universities, journals, and other organizations

Phase III data in treatment of renal cell carcinoma reported

Date:
October 1, 2012
Source:
European Society for Medical Oncology
Summary:
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were just released.

New results released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna may have important implications for patients.

New trial results on pazopanib and temsirolimus

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were just released.

Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney.

Prof Maria De Santis from Kaiser Franz Josef-Spital, Vienna, Chair of the ESMO 2012 Genitourinary program track (who was not involved in the studies) commented: "At this year's ESMO congress, three urgently awaited and highly ranked randomized phase III trials in the area of renal cell carcinoma are being presented. All three studies are important, although two of these studies are so called 'negative' studies (INTORACT and INTORSECT)."

"These studies are significant because they increase our knowledge about the use of targeted treatment options, in particular temsirolimus, sorafenib, bevacizumab and pazopanib," Prof De Santis said. "Most importantly, one of the studies, the COMPARZ trial, allows us to define a standard option in the front line treatment of renal cell carcinoma, because it was proven that pazopanib is non-inferior to sunitinib. In addition, being treated with pazopanib, patients experienced fewer troublesome side-effects and an increased quality of life."

COMPARZ trial: pazopanib and sunitinib similarly effective in first line treatment of metastatic renal cell carcinoma

The new drug pazopanib has similar efficacy to sunitinib in controlling metastatic renal cell carcinoma, the results of the phase III randomized, open-label COMPARZ trial show.

Sunitinib and pazopanib are both targeted drugs available for first line treatment of metastatic renal cell carcinoma. Sunitinib has been considered as the reference standard, although non-randomized trials have suggested similar efficacy with pazopanib, and less incidence of some side effects found troublesome to patients.

Dr Robert Motzer from Memorial Sloan Kettering Cancer Center, New York, USA and colleagues set out to compare the efficacy, safety, and quality of life for pazopanib and sunitinib in a global, 1100-patient phase III trial. The primary endpoint was to establish non-inferiority of progression-free survival, and safety and quality of life were evaluated as secondary endpoints, as well.

"The trial showed that pazopanib had similar efficacy (i.e non-inferiority) compared to sunitinib in first-line treatment of metastatic renal cell carcinoma," Dr Motzer said. "The main endpoint for assessment was progression-free survival, and we looked at other endpoints as well, including response, overall survival, safety and quality of life."

For both drugs, the median progression-free survival by the treating physician's assessment was slightly more than 10 months.

Both drugs resulted in side effects, but some of those recognized to be troublesome to patients, such as fatigue and skin sores, occurred with less frequency for pazopanib than with sunitinib, the researchers found.

"The quality-of-life questionnaires were in favor of pazopanib over sunitinib, and suggested improved tolerability for pazopanib over sunitinib," Dr Motzer said.

INTORSECT trial: Temsirolimus does not demonstrate superiority in survival over sorafenib in second-line treatment

The results of a phase III trial comparing two commonly used drugs in the second-line treatment of renal cell carcinoma suggest that temsirolimus does not improve survival over sorafenib in the second line setting.

The two drugs inhibit different cancer-associated molecules: temsirolimus targets mTOR, which regulates cell growth and proliferation, while sorafenib inhibits several tyrosine kinases, including VEGF receptors.

"This is the first head-to-head phase III trial comparing a VEGF inhibitor to an mTOR inhibitor in renal cell carcinoma, reporting final results. Hence, this trial will have important treatment implications for patients and physicians," said Dr Thomas Hutson from Texas Oncology-Baylor Charles A Sammons Cancer Center in Texas, USA.

Temsirolimus had demonstrated an overall survival benefit compared to interferon alfa in previously untreated patients with advanced renal cell carcinoma and poor prognostic features, but the drug's efficacy after treatment with a VEGF inhibitor was not known, Dr Hutson explained.

The INTORSECT Trial included 511 renal cell carcinoma patients from 112 sites, whose disease progressed after first-line sunitinib therapy and who had an ECOG performance status of 0 or 1. Median progression-free survival with temsirolimus was 4.28 months compared to 3.91 months with sorafenib. Median overall survival for the temsirolimus group was 12.27 months compared to 16.64 months for those who received sorafenib.

Based on these results, the researchers found that temsirolimus did not show superiority to sorafenib in the primary end point of progression-free survival or in the secondary end point of overall survival.

"This trial shows drugs that inhibit the VEGF pathway may be a better option than mTOR inhibitors for patients progressing on sunitinib," Dr Hutson said. "In addition, mTOR inhibitors may be appropriate for first line use for a select group of non-clear cell renal cell carcinoma patients and/or those patients with poor performance status." INTORACT Trial: bevacizumab plus temsirolimus offers no advantage over bevacizumab plus interferon A phase III trial has failed to confirm early clinical results with the combination of bevacizumab and temsirolimus in renal cell carcinoma, investigators from the INTORACT trial report.

The two drugs target separate molecular pathways involved in renal cell carcinoma, and early results had seemed promising, said Prof Brian Rini, a staff physician at the Cleveland Clinic's Taussig Cancer Institute in Cleveland, Ohio and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio.

The INTORACT trial, a global phase IIIb, randomized, open-label, multi-center study, compared temsirolimus plus bevacizumab with interferon plus bevacizumab as first-line treatment in 791 patients with predominantly clear cell metastatic renal cell carcinoma.

At the data cutoff for final analysis, 489 patients had independently assessed progression-free survival events. Median progression-free survival with the temsirolimus combination was 9.1 months, compared to 9.3 months in the interferon group. Median overall survival was 25.8 months in the temsirolimus group and 25.5 months for the interferon group.

This study failed to find an advantage to the combination of bevacizumab and temsirolimus over bevacizumab and interferon, therefore did not confirm preliminary results of this combination," Prof Rini said.


Story Source:

The above story is based on materials provided by European Society for Medical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology. "Phase III data in treatment of renal cell carcinoma reported." ScienceDaily. ScienceDaily, 1 October 2012. <www.sciencedaily.com/releases/2012/10/121001084342.htm>.
European Society for Medical Oncology. (2012, October 1). Phase III data in treatment of renal cell carcinoma reported. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2012/10/121001084342.htm
European Society for Medical Oncology. "Phase III data in treatment of renal cell carcinoma reported." ScienceDaily. www.sciencedaily.com/releases/2012/10/121001084342.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins